Adherence and motility of granulocytes from chronic myeloid leukemia (CML) patients was compared with that of granulocytes from normal subjects. The percentage of non-adherent granulocytes was significantly higher in untreated CML patients and patients in relapse and acute blastic crisis (ABC) (P less than 0.01). Chemotactic Index (C.I.) of granulocytes moving in a gradient of a synthetic chemoattractant F-Met-Leu-Phe was measured by time-lapse cinématography. While 84.5 +/- 3.53% of normal granulocytes were motile, only 30.3 +/- 14.7% granulocytes from untreated patients, 33.8 +/- 21.3% granulocytes from relapse patients and 36 +/- 9.9% granulocytes from ABC patients were found to be motile. The C.I. of motile granulocytes from CML patients was significantly lower in untreated patients (P less than 0.05), in patients in relapse (P less than 0.01) and in patients in ABC (P less than 0.05), as compared to that of normal granulocytes. Visualization of cytoplasmic actin by indirect immunofluorescence, revealed the presence of actin in granulocytes from patients in all stages of the disease. Thus, granulocytes from CML patients were defective in directional locomotion. Organized actin filaments were found in the small percentage of motile cells still found in CML patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0145-2126(85)90146-8 | DOI Listing |
Artif Organs
January 2025
International Renal Research Institute of Vicenza, Vicenza, Italy.
Background: Patients on maintenance hemodialysis (HD) face complications due to the accumulation of protein-bound uremic toxins, such as advanced glycation end products (AGEs), which contribute to inflammation, oxidative stress, and cardiovascular disease. Conventional HD techniques inadequately remove AGEs. This study evaluates the efficacy of the HA130 hemoadsorption cartridge combined with high-flux HD (HF-HD) in enhancing AGE removal.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Division of Hematology/Oncology, Changhua Christian Hospital, Changhua, Taiwan.
Rationale: Chylothorax is a rare adverse effect that is associated with dasatinib, a tyrosine kinase inhibitor administered for chronic myeloid leukemia (CML) treatment. Most reported cases have described standard dosing. In this case report, we described a 43-year-old male patient with CML who developed chylothorax after 4 years of low-dose dasatinib therapy.
View Article and Find Full Text PDFBiochem Pharmacol
January 2025
State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, PR China; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, PR China. Electronic address:
Chronic myeloid leukemia (CML) is a type of malignancy characterized by harboring the oncogene Bcr-Abl, which encodes the constitutively activated tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors targeting BCR-ABL have revolutionized CML therapy, native and acquired drug resistance commonly remains a great challenge. Thioredoxin 1 (Trx1) and glutamate-cysteine ligase (GCL), which are two major antioxidants that maintain cellular redox homeostasis, are potential targets for cancer therapy and overcoming drug resistance.
View Article and Find Full Text PDFAnn Intensive Care
January 2025
Anaesthesia and Intensive Care Medicine, School of Medicine, University of Galway, Galway, Ireland.
Objective: To understand the impact of both frailty and chronologic age on outcomes of weaning from invasive mechanical ventilation (MV).
Methods: The study population consisted of patients enrolled in the 'WorldwidE. AssessmeNt of Separation of pAtients From ventilatory assistancE (WEAN SAFE) study.
Mol Biol Rep
January 2025
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Introduction: Hematologic malignancies, originating from uncontrolled growth of hematopoietic and lymphoid tissues, constitute 6.5% of all cancers worldwide. Various risk factors including genetic disorders and single nucleotide polymorphisms play a role in the pathogenesis of hematologic malignancies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!